The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
Abstract Inhibitors of Bruton’s tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell lymphoma (MCL). However, clinical relapses following BTKi and CD19-directed CAR-T treatments are...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2024-06-01
|
| Col·lecció: | Biomarker Research |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s40364-024-00589-7 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|